🇺🇸 Arcus Biosciences, Inc.
Forum topic · RCUS · Company page: financials, ownership and filings
Join the discussion on Arcus Biosciences, Inc.
Loading…
Results announced on 4 November 2026
Arcus Biosciences, Inc. announced results on 4 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $9 million (down 65% from a year earlier) and a net loss of $128 million.
Results announced on 21 October 2026
Arcus Biosciences, Inc. announced results on 21 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $9 million (down 65% from a year earlier) and a net loss of $128 million.
Mutual funds: 238 funds hold $1.2 billion
238 mutual funds in 2 countries hold shares of Arcus Biosciences, Inc. worth $1.2 billion, about 27.4% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 121 funds added shares and 65 sold; on balance they bought $127 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.